VC Bob Nelsen argues that even if large pharma companies appropriate ideas or gain leverage over US biotech, their financial success is ultimately beneficial. Profitable pharma companies must deploy massive cash reserves, much of which flows back into the biotech ecosystem through M&A, funding the next generation.

The recent biotech funding "winter" thawed as large pharmaceutical companies began addressing their massive patent cliffs. This existential threat spurred a wave of M&A transactions, which in turn injected capital and confidence back into the market, enabling smaller biotechs to raise funds through follow-on offerings and IPOs.

After years of focusing on de-risked late-stage products, the M&A market is showing a renewed appetite for risk. Recent large deals for early-stage and platform companies signal a return to an era where buyers gamble on foundational science.

Successful acquisitions don't just benefit the acquired company's investors. These investors often reinvest their profits into new, earlier-stage ventures, providing crucial capital that fuels the entire biotech ecosystem's growth and innovation.

As large pharmaceutical companies shift focus to acquiring clinically validated assets, a gap has emerged in early-stage development. Smaller and mid-sized pharmas, unable to compete on price for late-stage assets, are now incentivized to take on more risk and partner earlier, driving innovation.

The current M&A wave is unique because it includes both public and private company takeouts. This creates a robust capital recycling engine, providing quick returns to VCs (from private sales) and public specialist funds (from public takeouts). This capital is then immediately redeployed into new early and later-stage companies, sustaining the innovation ecosystem.

The biotech ecosystem is a continuous conveyor belt from seed funding to IPO, culminating in acquisition by large biopharma. The recent industry-wide stall wasn't a failure of science, but a halt in M&A activity that backed up the entire system.

M&A is often framed as a win, but it can be detrimental to patients. The acquisition of an aggressive, fast-moving biotech by a large pharma company can lead to slowed development timelines and more conservative regulatory strategies, ultimately delaying access to life-saving treatments.

While celebrated, the current wave of high-value acquisitions of promising companies like Sonora and Halda has a downside. It removes potential standalone success stories from the market, potentially weakening the public biotech index and depriving investors of future mid-cap growth engines.